SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

Search

Orion Oyj (Class B)

Slēgts

63 1.61

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

63

Max

63.05

Galvenie mērījumi

By Trading Economics

Ienākumi

-12M

61M

Pārdošana

-80M

355M

P/E

Sektora vidējais

25.746

40.527

EPS

0.44

Dividenžu ienesīgums

2.59

Peļņas marža

17.287

Darbinieki

3,943

EBITDA

202M

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.59%

2.40%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.5B

9B

Iepriekšējā atvēršanas cena

61.39

Iepriekšējā slēgšanas cena

63

Orion Oyj (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. jūl. 23:55 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments -- Market Talk

2025. g. 6. jūl. 22:35 UTC

Iegādes, apvienošanās, pārņemšana

South32 Expects to Complete Transaction in Late 2025

2025. g. 6. jūl. 22:35 UTC

Iegādes, apvienošanās, pārņemšana

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

2025. g. 6. jūl. 22:34 UTC

Iegādes, apvienošanās, pārņemšana

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

2025. g. 5. jūl. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 15:57 UTC

Tirgus saruna

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Tirgus saruna

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Received All Required Authorizations

2025. g. 4. jūl. 15:48 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Agreement Was Announced on Dec. 19

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025. g. 4. jūl. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025. g. 4. jūl. 14:30 UTC

Iegādes, apvienošanās, pārņemšana

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025. g. 4. jūl. 13:53 UTC

Tirgus saruna

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. jūl. 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Salīdzinājums

Cenas izmaiņa

Orion Oyj (Class B) Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.